NCT02249182 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

November 5, 2014

Primary Completion Date

June 15, 2018

Study Completion Date

August 24, 2018

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

LDV/SOF FDC administered orally once daily

DRUG

RBV

Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight

Trial Locations (31)

Unknown

Birmingham

Los Angeles

San Francisco

Aurora

Washington D.C.

Atlanta

Indianapolis

Louisville

Baltimore

Boston

St Louis

Omaha

New York

Chapel Hill

Cincinnati

Columbus

Philadelphia

Nashville

Dallas

Fort Worth

San Antonio

Seattle

Morgantown

Newcastle

Westmead

Parkville

Auckland

Birmingham

Leeds

London

Glasgow